Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-seq™️ platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients.
Company Details
- Employees
- 38
- Founded
- -
- Address
- Science Park 301,
- in****@****ech.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://scenicbiotech.com/about
- Keywords
- Medicine, Rare disease, Science, Technology, Pharmaceuticals, Biology, Biotechnology, Orphan Disease, Neurological Disease, Metabolic Disease, Drug Discovery, Drug Development, Platform Technology.
- HQ
- Amsterdam, Noord-Holland
Scenic Biotech Questions
Scenic Biotech's website is https://scenicbiotech.com/about
Scenic Biotech's LinkedIn profile is https://www.linkedin.com/company/scenic-biotech
Scenic Biotech has
38 employees.
View email and phone details for 38
employees at Scenic Biotech.
Scenic Biotech's industry is
Biotechnology Research
Scenic Biotech's top competitors are
Neogene Therapeutics,
Uniqure,
Lava Therapeutics N.v.,
Leyden Labs,
Merus N.v.,
Batavia Biosciences,
Proqr Therapeutics,
Genmab,
Lumicks,
Vectory.
Scenic Biotech's support email address is info@scenicbiotech.com
Scenic Biotech's categories are Biotechnology Research
Scenic Biotech's founding year is 2017
